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Summary Prevention of acid is important in gastroesophageal reflex disease (GERD)-related
asthma therapy. Proton pump inhibitors (PPI) and H2-receptor blockers have been reported
as useful therapies for improving asthma symptoms. GERD prevalence is high in asthma;
however, methods for validating GERD existence based on questionnaire, endoscopic exami-
nation and 24h-pH monitoring do not directly determine GERD influence on the airway.
Exhaled breath condensate analysis is a novel and non-invasive tool for assessing information
directly from the airway. Breath collected by cooling can be applied to pH, 8-isoprostane and
cytokine analysis in patients with GERD-related asthma, and the pH and 8-isoprostane levels
have been shown to reflect the effects of PPI therapy in these patients. Although the analysis
of cooled breath has not yet been established in a clinical setting, this method is expected to
provide a novel tool for monitoring airway acidification associated with GERD.
Key Words: exhaled breath condensate, asthma, gastroesophageal reflux disease (GERD),
isoprostanes, proton pump inhibitor
Introduction
The prevalence of gastroesophageal reflex disease
(GERD) in asthma patients has been reported to be as high
as ~30–80% as compared with non-asthmatic subjects [1].
GERD is generally assessed by 24h-pH monitor, questionnaire
or endoscopy. The prevalence of GERD among asthma
patients evaluated by 24h-pH monitoring has been reported
variously as 32% [2] and 82% [3]. By the questionnaire for
the diagnosis of reflux disease (QUEST) method [4], the
prevalence of GERD in asthma patients was found to vary
from 42% [5] to 69.2% [6], and by endoscopic examination,
hiatal hernia was found to be present in about 40% [7] and
esophagitis in 47% [6] of asthmatic patients. Theoretical
mechanisms to explain the prevalence of GERD-related
asthma are based on  aspiration theory or reflux theory.
Airway inflammation seems to be caused either by vagal
reflux leading to acid exposure of the esophagus [8] or by
microaspiration of acid to the airway [9].
Anti-acid therapy has been reported to be effective for
treating GERD-related asthma [10–12]. Proton pump inhibitors
(PPIs) and H2-receptor blockers (H2-blockers) are beneficial
in GERD-related asthma; however, the duration of anti-acid
therapy and the dosage of these drugs have not been
established, and to date no suitable methods have been
developed for directly and non-invasively evaluating airway
acidification by GERD. Although there are established
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methods for assessing GERD, including 24h-pH monitor,
questionnaire and endoscopic examination, these methods
do not directly evaluate airway acid stress due to GERD.
Exhaled breath condensate (EBC) has been recently
reported as a new tool for monitoring airway condition in
various pulmonary diseases and has the advantage of non-
invasive, reproducible and objective evaluation [13, 14]. The
exhaled breath is collected through a mouthpiece attached to
cooling equipment, and the collected fluid can be applied to
cytokine assay or pH measurement. In this article, we review
the adaptation of EBC analysis to monitoring airway acid
stress and anti-acid therapy in GERD-related asthma.
Collection of Exhaled Breath Condensate
The surface of the lower airway is covered with airway
lining fluid (ELF), and exhaled breath includes various non-
volatile substances as an ELF aerosol [15]. The substance of
ELF is obtained by cooling breath at −20°C, and the principle
of the cooling equipment is shown in Fig. 1. EcoScreen®
(Jaeger, Berlin, Germany) and RTubeTM (Respiratory Research,
Inc, Virginia) are systems that are commercially available at
present. Patients breathe tidally through a mouthpiece
attached to the EBC equipment for 15 min, while wearing a
nose clip. By this method, approximately 1 to 2 ml of breath
condensate is collected, depending on the patients’ breathing
tidal volume. The  samples collected should be frozen
immediately and stored at −80°C. Storage for more than
several months is not recommended. The sample can be used
to measure various cytokines, H2O2, pH or other biomarkers.
Contamination of EBC by saliva should be examined by
measuring the amylase concentration of samples, and the
reproducibility of sample measurements should be confirmed.
For pH measurements, in order to avoid contamination with
ambient CO2, it is recommended that  the EBC sample
should be treated with gentle nitrogen bubbling. The pH
levels of EBC differ by the  two commercially available
collection devices described above, and storage of samples
for 8 weeks without deaeration can significantly influence
measurements [16].
Analysis of EBC in GERD-Related Asthma
Analysis of EBC in asthma patients has been intensively
performed. LeukotrienB4, interleukin(IL)-4, IL-8, IL-17, tumor
necrosis factor (TNF)-α, regulated on activation normal T-cell
expressed and presumably secreted (RANTES), interferon-
γ-inducible protein 10, transforming growth factor(TGF)-β,
macrophage inflammatory protein1a, and 1b in EBC are
increased in asthma patients [17, 18]. Evaluation of the pH
of EBC has also been reported to reflect airway acidity in
asthma patients (Table 1). The pH of healthy subjects is in
the range of ~7.5 to 7.7; however, with asthma exacerbation
the pH decreases markedly to about 5.5 to 6.0. Severity of
asthma affects the decrease in airway pH, and airway pH in
patients with moderate asthma is lower than that in patients
with mild asthma (Table 1) [19–21].
Recently, measurement of EBC pH has been used to
evaluate the influence of GERD on airway acidity [22]. The
pH levels of EBC in asthma patients with GERD are lower
than those in asthma patients without GERD (Table 1). In
terms of possible mechanisms underlying the effects of
GERD on EBC pH in asthma, studies of induced sputum
have shown that GERD evaluated 24h-pH monitoring causes
neutrophilic inflammation accompanied by an increase in
IL-6 levels in the airway, and also that  eosinophilic
inflammation is exaggerated in GERD-related asthma, as
compared with patients with GERD alone [23]. These
inflammatory mechanisms might cause the changes in EBC
pH in GERD-related asthma. Changes in pH are also
observed in various pulmonary diseases. Chronic obstructive
pulmonary disease (COPD) and idiopathic pulmonary fibrosis
(IPF) have been found to decrease the pH of  EBC, and
unstable disease conditions in asthma were associated with
decreased  EBC pH  in our study (Fig. 2). In addition, in
cystic fibrosis the pH of EBC has also been reported to be
decreased [24]. In terms of the mechanisms underlying the
changes in airway pH, the Na+-H+ exchanger, the H+-K+
ATPase, the vacuolar K+ ATPase, H+ channels and the
glutaminase pathway have been proposed to contribute to
Fig. 1.  Attachment of exhaled breath condensate. Exhaled air is
cooled through the attachment at −20°C. Sample is col-
lected at the bottom of attachment as liquid or ice.Acid Stress Marker in Asthma with GERD
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deviations in the intracellular and extracellular pH of the
airway  [25,  26]. Although pH measurement seems to be
useful to evaluate lower airway acidification [15, 20, 26], it
is  still debated whether pH levels determined  by orally
collected EBC reflect airway acidity due to contamination
by NH4 and saliva [27–30]. To determine the efficacy of
EBC pH measurement for assessing GERD, further studies
are needed on a larger number of GERD patients and on
other GERD-related pulmonary diseases; in addition, more
suitable markers of GERD should be developed.
The oxidative stress markers isoprostanes are eicosanoids
that are non-enzymatically produced by the  oxidation of
cell membrane and plasma phospholipids. Among the
isoprostanes, 8-isoprostane (8-iso) has been reported as a
tissue marker of oxidative stress [31]. Oxidative stress is
reported to be increased in asthmatic subjects, as reflected
by the 8-iso levels in EBC [32]. In healthy subjects, the
levels of 8-iso present in EBC are in the range of 3.5 to
20 pg/ml; in asthma patients, however, these 8-iso levels are
markedly higher. Furthermore, if asthma severity is divided
into mild, moderate and severe categories, then the severity
is correlated with the increase in airway 8-iso; in other
words, the 8-iso level is higher in patients with moderate
asthma (24 to 40 pg/ml) than in those with mild asthma (16
to 25 pg/ml) (Table 1) [20–22]. Furthermore, the levels of 8-
iso are higher in asthma patients with GERD than in those
without GERD (Table 1), and  8-iso levels are higher in
patients with moderate asthma with GERD than those with
moderate asthma without GERD. The levels of 8-iso in
asthma patients with GERD are probably higher than those
in patients with the same severity of asthma but without
GERD. In patients with GERD alone, the 8-iso levels are
also higher than in healthy subjects [23]. The mechanisms
underlying the GERD-induced production of 8-iso in the
airway remain unresolved.
Reflux mechanisms or microaspiration mechanisms due
to GERD [8, 9] might increase the oxidative stress-related
production of 8-iso in the airway epithelium. The action of
8-iso on asthma is considered to be mediated via the Rho G-
protein in bronchial smooth muscle. 8-Iso acts on Rho and
Rho-kinase signaling via the thromboxane A2 receptor [33].
The Rho/Rho-kinase pathway plays an important role in
bronchial smooth muscle constriction and inflammation;
therefore, elevated 8-iso levels possibly stimulate the
bronchial smooth muscle in asthma pathogenesis [34–36].
Table 1. pH and 8-isoprostane levels in healthy subjects and asthma patients measured by exhaled
breath condensate
Disease condition pH 8-iso pg/ml Reference
Healthy 7.65 ± 0.20 [19]
Asthma exacebration 5.23 ± 0.21 [19]
Stable asthma 7.8 ± 0.1 [19]
Healthy 7.57(CI, 7.51–7.64) 20 ± 7.0 [20]
Mild asthma 7.6 (CI, 7.55–7.65) 25 ± 7.0 [20]
Moderate 7.27 (CI, 7.15–7.39) 40 ± 9.0 [20]
Healthy  7.70 (CI 7.62–7.74) 3.5 (CI 2.6–7.9) [21]
Mild asthma 7.53 (CI 7.41–7.68) 16.2 (CI11.7–19.1) [21]
Healthy 7.5 ± 0.2 6.6 ± 1.2 [22]
Moderate asthma without GERD 7.3 ± 0.6 24.6 ± 3.8 [22]
Moderate asthma with GERD 7.2 ± 0.1 32.7 ± 3.4 [22]
Healthy  6.9 (CI 5.6–9.7) [23]
Mild asthma without GERD 17.9 (CI 8.9–23.8) [23]
Mild asthma with GERD 26.5 (CI 15.1–36.5) [23]
Fig. 2.  pH levels of various pulmonary diseases in healthy
subjects, stable asthma, unstable asthma, COPD and
IPF. Unstable asthma is defined as follows: 1. daytime
symptoms is more than twice/week, 2. Presence of
limitation of activity and nocturnal symptoms/
awakened, 3. Needed for rescue treatment is more than
twice/week.Y. Shimizu et al.
J. Clin. Biochem. Nutr.
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Thus, measuring the levels of 8-iso in EBC would seem to be
useful for the evaluation for GERD-related asthma, and
targeting this pathway might be a novel strategy in the
treatment of GERD-related asthma.
Changes of Breath Marker in PPI Treatment for
GERD-Related Asthma
PPIs and H2-blockers have been reported to be beneficial
in GERD-related asthma [10]; however, the duration of anti-
acid therapy and the suitable dosage of these drugs have not
been established. In addition, to date there are no non-
invasive monitoring methods to determine the on-off anti-
acid therapy under directly and subjectively observation on
airway acidification. EBC analysis is a considered as a novel
approach to monitor airway condition that is non-invasive,
direct and objective. The pH and 8-iso levels in EBC in
patients with moderate asthma and GERD were found to be
improved by lansoprazole at a dosage of 30 mg/day, along
with improvements of GERD symptoms; by contrast, in
patients with moderate asthma but no GERD, the levels of
these breath markers were not changed by this therapy
(Fig. 3) [22]. This finding indicates that the pH and 8-iso
levels measured in EBC would be useful markers for the
diagnosis of GERD-related asthma, and that the these
breath markers might be direct and objective markers for
determining the intervention timing of anti-acid therapy.
In another study, the prevalence of abnormal acid reflux
was found to be high in IPF patients. PPIs were used to treat
IPF at a dose of omeprazole 20–40 mg/day; however, this
therapy did not suppress the abnormal acid reflux, as
evaluated by 24h-pH monitor [37]. The author suggested
that further studies are needed to assess whether the
abnormal acid represents an important risk factor for IPF
exacerbation and to assess the optimal dose for suppression
of acid [37]. In COPD patients, the prevalence of GERD was
reported to be high and the exacerbation of it appeared to
be associated with GERD [38]. Although measurement of
EBC pH was not performed in those studies, and not all of
deviation in the EBC pH reflects the effects of GERD on the
airway, GERD appears to be a risk factor of exacerbation
and progression in pulmonary disease.
Screening of GERD-Related Asthma
A proposal for screening of GERD-related asthma is
shown in Table 2. Asthma severity should be divided into
mild, moderate and severe categories [39]. When asthma
patients show either difficult-to-control asthma or non-
typical symptoms relative to the estimated severity, it is
important to suspect the GERD affects from one of the
differential diagnosis.  Lung cancer should be ruled out.
GERD is known to cause persistent cough and asthma-like
symptoms [40], and questions concerning GERD-related
symptoms provide diagnostic clues to GERD-related asthma.
To screen for GERD existence, the QUEST score [4] and F-
scale [41] are useful; in addition, doctors should ask patients
about the timing of asthma exacerbations in relation to food
intake or excessive intake. Because questionnaires are
subjective evaluation methods for GERD and are not
necessarily suitable for detecting asymptomatic GERD [42],
measurement of pH and 8-iso levels in EBC has the potential
Fig. 3.  Changes of pH and 8-isoprostane levels by PPI therapy in QUEST≧4 group and QUEST<4 group in moderate asthmatic
patients. QUEST≧4 is indicates existence of GERD. Statistically significant differences between groups are expressed by
*p<0.05. Reprinted with permission [22].Acid Stress Marker in Asthma with GERD
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to provide  another validation method for GERD-related
asthma. In terms of anti-acid therapy, PPIs seem to be more
useful than H2-blockers in GERD-related asthma [12]. The
proposed PPI therapy is recommended for two to three
months. Furthermore, it is important to educate patients
about improving their lifestyle and diet. If asthma does
not improve, and GERD-related asthma is still suspected,
endoscopic examination, 24h-pH monitoring and consultation
with a gastroenterologist are needed.
Conclusion
Measurement of pH and 8-iso levels in EBC seems to be
useful for evaluating GERD influence on airway condition
and the efficacy of PPI therapy in GERD-related asthma;
however, one study has reported that an improvement in
GERD-related cough by PPI therapy is not associated with
changes in EBC pH or capsaicin cough response [43]. A
study comparing biomarkers in EBC and bronchoalveolar
lavage fluid (BAL) found no correlation in pH, 8-iso, H2O2
and NO. For example, 8-iso levels were much higher in EBC
than in BAL, and pH was also higher in EBC than in BAL
[44]. Thus, EBC was not necessarily found to be a reflection
of BAL fluid for the following reasons. EBC is collected
from a larger area than BAL, contamination with blood
could occur during BAL collection, and there are differences
in dilution between the two methods [44]. Thus, although
observation of pH and 8-iso in EBC is relatively easy, the
levels of both breath markers have not been yet established
as a reflection of airway condition affected by GERD. Factors
including differential severity of the pulmonary disease itself,
receiving medication, body mass index, meals and sample
storage conditions could affect the values measured in EBC
[45]. In addition, further methodological improvement is
needed to reproducibly obtain reliable data [46].
To determine the efficacy of EBC measurement in GERD-
related asthma in a clinical setting, further studies are needed
on larger numbers of both patients with GERD alone and
patients with GERD-related pulmonary diseases. In addition
to pH and 8-iso measurements, other markers of airway
acidification by GERD expected to be developed.
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